Pancreatic ductal adenocarcinoma (PDA) is a malignant neoplasm derived from the cells of the pancreatic ductal system. This form of cancer is characterized by an aggressive course and high mortality, which is due to both late diagnosis and the complexity of surgical intervention on the pancreas. PDA accounts for about 85% of all pancreatic cancer cases and is usually diagnosed at late stages, which limits the possibilities of effective treatment. Clinically, the disease manifests itself with nonspecific symptoms such as loss of appetite, weight loss, abdominal pain and jaundice. Given its high invasiveness and metastatic potential, PDA requires a multidisciplinary approach to diagnosis and treatment.
History of the disease and interesting historical facts
The history of pancreatic ductal adenocarcinoma dates back to the early 20th century, when systematic studies of pancreatic cancer first began. In 1910, German pathologist Wilhelm Reichel described the disease, highlighting its features and clinical manifestations. In the following decades, large-scale studies were conducted to understand the pathogenesis and clinical aspects of pancreatic cancer. Thus, in the 1970s, the association between smoking and an increased risk of developing PDA became known, which opened up new horizons for risk factor research. Diagnostic methods have also evolved: from the first X-ray studies to modern imaging methods such as magnetic resonance imaging and computed tomography, which significantly increased the level of diagnosis of this disease.
Epidemiology
According to the World Health Organization (WHO), pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide. Statistics show that the incidence of PDA varies by region and country level of development. In the United States, approximately 60,000 new cases are reported each year, while in Europe and other developed countries, the rate is comparable. PDA occurs more often in men than in women, with the peak incidence occurring in the 65-79 age group. Studies also show that certain ethnic groups, such as Africans and Hispanics, have higher incidence rates.
Genetic predisposition to this disease
Genetic factors play a significant role in the pathogenesis of pancreatic ductal adenocarcinoma. In particular, hereditary mutations in the BRCA2, PALB2, and CDKN2A genes are associated with an increased risk of developing this type of cancer. Such mutations can lead to disruption of cell cycle control and, as a consequence, to the initiation of carcinogenesis. In addition, mutations in the KRAS, TP53, and SMAD4 genes have been found that are associated with disease progression. According to studies, about 10% cases of PDA have a hereditary predisposition, which emphasizes the importance of genetic counseling for relatives of patients with pancreatic cancer.
Risk factors for the development of this disease
There are many factors that contribute to the development of pancreatic ductal adenocarcinoma. These include:
- Smoking: Studies have shown that smokers have a two to three times higher risk of developing PPA compared to nonsmokers.
- Chronic pancreatitis. Long-term inflammation of the pancreas promotes cellular changes and can lead to carcinogenesis.
- Obesity: Being overweight is associated with an increased risk of pancreatic cancer.
- Diabetes mellitus. Diabetes can both precede and develop in parallel with PPA.
- Heredity: Having a family history of pancreatic cancer increases your risk of developing the disease.
- Age. The likelihood of developing malignant tumors increases with age.
Diagnosis of this disease
Diagnosis of pancreatic ductal adenocarcinoma includes several stages and methods:
- Main symptoms: Patients may complain of vague abdominal pain, loss of appetite, jaundice, weight loss and deterioration of general condition.
- Laboratory tests: Determination of the serum marker CA 19-9 may be useful, although its specificity and sensitivity are limited.
- Radiological examinations: Ultrasound, CT and MRI are used to visualize the tumor and assess the stage of the disease.
- Other diagnostic tests: Endoscopic retrograde cholangiopancreatography (ERCP) may be used to obtain a biopsy.
- Differential diagnosis. It is necessary to exclude other diseases, such as chronic pancreatitis, gallbladder cancer and other abdominal organs.
Treatment
Treatment of pancreatic ductal adenocarcinoma is multidisciplinary and depends on the stage of the disease. The main approaches include:
- General treatment: The main treatment is surgery if the tumor is detected at an early stage and there are no metastases.
- Pharmacological treatment: Chemotherapeutic drugs such as gemcitabine and folfirin are used to combat metastatic disease.
- Surgical treatment: Operations such as pancreaticoduodenectomy are used to remove the tumor.
- Other treatments: Radiation therapy may be considered as an additional treatment, especially in cases of locally advanced disease.
List of medications used to treat this disease
The main drugs used to treat pancreatic ductal adenocarcinoma include:
- Gemcitabine
- Folfirinok (FOLFIRINOX)
- Erutinib
- Naboxil
- Paclitaxel
Disease monitoring
Disease monitoring includes regular follow-up examinations to assess the patient's condition dynamics. The prognosis depends on the stage of the disease at the time of diagnosis, as well as the response to treatment. Complications may include the development of metastases, pain, and deterioration in quality of life. Regular monitoring of the CA 19-9 marker level can help in assessing the effectiveness of treatment and early diagnosis of relapse.
Age-related features of the disease
Pancreatic ductal adenocarcinoma is more common in older people, but cases of the disease in younger patients are also observed. In older people, the disease often has a more aggressive course and is associated with high comorbidity, while younger patients may have rarer genetic forms of the disease, which requires an individual approach to diagnosis and treatment.
Questions and Answers
- What are the main symptoms of pancreatic ductal adenocarcinoma? The main symptoms include abdominal pain, loss of appetite, unintentional weight loss and jaundice.
- How is PPA diagnosed? Laboratory tests, radiological methods and biopsy are used to finally verify the diagnosis.
- What are the risk factors for developing PPA? These include smoking, obesity, chronic pancreatitis and hereditary predisposition.
- What is CA 19-9 marker? It is a biomarker that can be used to assess treatment efficacy and monitor disease, despite limited specificity and sensitivity.
- What is the treatment for PPA? Treatment may include surgery, chemotherapy, and radiation therapy depending on the stage of the disease.
